Neuromuscular junction diseases. Diseases of myoneural junction and muscle
Conditions
Interventions
Intervention group: For patients, initially, intravenous ketamine is titrated at a dose of 2 mg/kg until the desired response is achieved (moderate to deep sedation until the patient is still),IV. To
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
2 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1-Patients who have a history of NMJ symptoms including ptosis, fatigue, voice change and swallowing problems.2- Patients do not have enough cooperation to perform the diagnostic test without deep sedation.3- Perform deep sedation with ketamine drug based on consultation of lung, anesthesia and heart.
Exclusion criteria
Exclusion criteria: 1- Allergy to ketamine drug2- Any heart problem (including low blood pressure, heart rhythm disorder) and lung3- Facial deformity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of repeated nerve stimulation test. Timepoint: At the end of the test. Method of measurement: Time in minutes.;Heart rate during the test. Timepoint: At the beginning of the test, every 15 minutes during the test, at the end of the test. Method of measurement: Cardiopulmonary monitor.;Oxygen saturation percentage during the test. Timepoint: At the beginning of the test, every 15 minutes during the test, at the end of the test. Method of measurement: Cardiopulmonary monitor.;Ketamine dosage. Timepoint: At the end of the test. Method of measurement: Medical record.;Atropine dosage. Timepoint: At the end of the test. Method of measurement: Medical record.;Any complications during the test. Timepoint: At the beginning of the test, during the test, at the end of the test. Method of measurement: Medical record. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFaeze Karamiani
Shahid Beheshti University of Medical Sciences
Outcome results
None listed